Global pharmaceutical company Allergan has announced that it will acquire US-based biotechnology company Bonti.
UK aesthetic distributor Schuco Aesthetics has relocated its premises from Watford to Leavesden Park.
A clinical study conducted by global pharmaceutical company Allergan suggests that higher doses of Botox Cosmetic (onabotulinumtoxinA) to treat moderate to severe glabella lines produces greater duration of treatment effect.
Aesthetic PR and communications consultancy Kendrick PR has acquired PR agency, EBWPR.
Global pharmaceutical company Allergan has announced plans to invest more than €42 million (over £36 million) in an expansion.
Interest in medial aesthetics is at an all-time high according to a new report by global pharmaceutical company Allergan, which questioned individuals about their perceptions of beauty.
Global biopharmaceutical company AbbVie has completed its acquisition of Allergan plc following regulatory approval of all government authorities.
Allergan recently unveiled new data from a multicenter, randomised, double-blind trial that showed 20 Units of VISTABEL® was as effective as 30 Units of Bocouture® for the treatment of moderate to severe glabellar lines. The study results were presented during the 7th European Masters in Anti-Ageing Medicine (EMAA) congress in Paris. “This new study underlines why it is important that medical aesthetic practitioners are aware of the differences between each of the botulinum toxins when selecting the most appropriate treatment for their patients,” comments Dr Moers-Carpi from Munich, Germany and lead investigator for the study. “With botulinum toxin manufacturers each having unique definitions of a unit, aesthetic practitioners should be vigilant in adopting the treatment protocol set by the respective manufacturer and not translating previous experience with one toxin to another.”
Superdrug has launched the Skin Renew Service, which will provide anti-wrinkle and skin rejuvenation injectable treatments.
Global pharmaceutical company Allergan has announced it will purchase clinical-stage biotechnology company Vitae Pharmaceuticals.